Oliver Colvile – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Oliver Colvile on 2016-01-18.
To ask the Secretary of State for Health, what steps his Department is taking to simplify and make more accessible the diagnostic pathway in order to improve speed of diagnosis and access to support.
Jane Ellison
In September 2015, the NHS England Board approved the development of a personalised medicine strategy for the National Health Service which will be based around four overarching principles: the prediction and prevention of disease; more precise diagnoses; targeted and personalised interventions; and a more participatory role for patients.
The strategy will build on the 100,000 Genomes Project, which is moving the NHS to a new model of diagnosis and treatment based on the understanding of underlying genetic causes and drivers of disease and a comprehensive phenotypic characterisation of the disease (rather than deduction from symptoms and individual diagnostic tests). Personalised medicine informs the selection of the most appropriate treatment and better outcomes for individual patients – the right drug at the right time, earlier screening and treatment, smarter monitoring and the adjustment of treatments.
Furthermore, the Independent Cancer Taskforce recognised the need for more accessible molecular diagnostic provision in their report ‘Achieving World-Class Cancer Outcomes’ published in July 2015. In September 2015, the Department confirmed a commitment from NHS England to implement the Taskforce’s recommendations on molecular diagnostics.
NHS England is currently working with partners across the healthcare system to determine how best to take forward the recommendations of the Taskforce, and has appointed Cally Palmer as National Cancer Director to lead on implementation, as well as new cancer vanguards to redesign care and patient experience.
She has set up a new Cancer Transformation Board to implement the strategy, and this met for the first time on Monday 25 January 2016. There will also be a Cancer Advisory Group, chaired by Sir Harpal Kumar, to oversee and scrutinise the work of the Transformation Board. Timeframes and phasing for implementation will be dependent on the final financial settlement reached as a result of the spending review.
